mRNA therapeutics in cancer immunotherapy.
Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. · 2021
Read mRNA therapeutics in cancer immunotherapy. by Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8047518.txt.
Description
Beck and co-authors review mRNA therapeutics in cancer immunotherapy. Synthetic mRNA can template any protein or peptide a designer chooses. Production scales fast under good manufacturing practice. That suits both shelf-ready cancer vaccines and personal neoantigen vaccines. The molecule also wakes innate immune sensors, acting as its own adjuvant.
The review covers how chemistry tunes that behavior. Nucleoside changes and cleanup of double-stranded RNA calm unwanted immune noise. Protein output then lasts longer. Nanoparticle carriers lift delivery into cells and toward lymph nodes. With them, mRNA can deliver cytokines, costimulatory receptors, or antibodies. Steady, brief production may beat recombinant proteins on safety. Even CAR-T cell therapy can borrow the trick. The authors close with the shifting clinical landscape.
Catalog record
| CREATOR | Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 125 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |